|
Match
|
Document |
Document Title |
|
|
7381704 |
Methods for use of short bioactive peptides
Short bioactive peptides containing phenylalanine, leucine, alanine, and lysine residues are disclosed. The peptides can be used in antibacterial, antifungal, anticancer, and other biological...
|
|
|
7381699 |
Reagents and methods for smooth muscle therapies
The present invention provides novel polypeptides comprising heat shock protein 20(HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth...
|
|
|
7381698 |
Methods for treatment of acute pancreatitis
The invention relates generally to methods for treating acute pancreatitis in patients. The methods comprise administering a therapeutically effective amount of a pharmaceutical composition...
|
|
|
7378095 |
Methods of treating type I diabetes by blocking VEGF-mediated activity
Methods of treating diabetes in mammals, particularly humans, by blocking or inhibiting VEGF-mediated activity. A preferred inhibitor of VEGF-mediated activity is a VEGF antagonist such as the VEGF...
|
|
|
7378392 |
Bone and cartilage inductive proteins
Purified cartilage and/or bone inductive proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and...
|
|
|
7378394 |
Sustained-release microparticle preparation of human growth hormone and process for producing thereof
Provided is a sustained-release microparticle preparation of a human growth hormone which combines biodegradability with sustained-release performance while avoiding the use of an organic solvent...
|
|
|
7378393 |
Recombinant anticoagulant proteins
Novel recombinant anticoagulation proteins, methods of their use and methods of their production are described. In particular, recombinant fusions of annexin V (ANV) and Kunitz protease inhibitors...
|
|
|
7378395 |
Mutants of bone morphogenetic proteins
The present invention relates to novel mutants of bone morphogenetic proteins (BMPs) useful as inhibitors of heterotopic ossification. Specifically, the present invention related to novel mutants...
|
|
|
7378388 |
Method of utilizing neurotrophins to manipulate reproductive capacity
Methods and kits are provided for manipulating and predicting the reproductive capacity of a female subject. The presence of endogenous neurotrophins and addition of exogenous neurotrophins,...
|
|
|
7378098 |
CXC chemokine receptor 4 agonist peptides
In accordance with various aspects of the invention, CXCR4 agonists, including SDF-1 polypeptides and SDF-1 polypeptide homologues, may be used in reducing the rate of hematopoietic cell...
|
|
|
7374889 |
Human sphingosine-1-phosphate phosphatase and inhibition methods
The present invention provides polynucleotides and polypeptides of a human sphingosine-1-phosphate phosphatase, referred to herein as hSPP1. The polynucleotides and polypeptides are used to further...
|
|
|
7375084 |
Highly phosphorylated and sulfated recombinant factor IX
The present invention relates to a purified recombinant blood coagulation factor IX (rFIX) preparation, wherein at least 25% of the rFIX in the preparation is fully phosphorylated and sulfated, a...
|
|
|
7374774 |
Electroprocessed material made by simultaneously electroprocessing a natural protein polymer and two synthetic polymers
The invention is directed to novel compositions comprising an electroprocessed material and a substance, their formation and use. The electroprocessed material can, for example, be one or more...
|
|
|
7374769 |
Method for treating a trigeminal neuralgia by peripheral administration of a neurotoxin
Methods for treating a trigeminal neuralgia by peripheral administration to a patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin.
|
|
|
7375083 |
Pharmaceutical compositions for prevention of overdose or abuse
The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause...
|
|
|
7371721 |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
The present invention relates to methods for prevention and treatment of bone-related disorders and calcium homeostasis related syndromes using a GLP-2 molecule or GLP-2 activator either alone or...
|
|
|
7371393 |
Methods for reducing fecal shedding
The present invention provides methods for reducing shedding in an animal. Generally, the method includes administcriirn to an animal a composition including siderophore receptor polypeptides and...
|
|
|
7371734 |
Oligonucleotide compositions and their use for the modulation of immune responses
The present invention relates to 3′-OH, 5′-OH polynucleotide sequence compositions and methods for activating an immune response in an individual, and more preferably, for activating antigen...
|
|
|
7371726 |
Neutralizing GDF8 epitope-based growth enhancing vaccine
The invention provides new, specific antigenic peptides from the protein GDF8. The invention also provides fusion proteins comprising the new peptides, immunogens and vaccines based on the new...
|
|
|
7371388 |
Treatment of Sjogren's syndrome by administration of TR18 polypeptides
The present invention relates to TR18 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR18 protein. TR18 polypeptides are also provided as are vectors, host...
|
|
|
7371722 |
Pharmaceutical preparations and medicine capable of generating and/or containing thrombin
The invention relates to a pharmaceutically active substance for producing a drug that is capable of generating thrombin or that contains thrombin and compositions comprising thereof. The...
|
|
|
7368425 |
Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
The present disclosure teaches analogs of human chemokines and methods of using them in the prevention, treatment, and ameliorization of diseases that can benefit from therapeutic angiogenesis. The...
|
|
|
7368432 |
Conotoxin peptides
The invention relates to relatively short conotoxin peptides, about 10-20 residues in length as described herein, which are naturally available in minute amounts in the venom of the cone snails or...
|
|
|
7368115 |
Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (PACAP)
The present invention relates to a method of increasing the number and/or differentiation of neural stem cells and/or neural stem cell progeny using pituitary adenylate cyclase-activating...
|
|
|
7368119 |
Compositions and methods for WT1 specific immunotherapy
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an...
|
|
|
7368106 |
Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state
The invention provides a method of treating or preventing a pathologic state in a mammal. The method comprises administering to the mammal a promoter of T-cell expansion and an inducer of CD40...
|
|
|
7368429 |
Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
Human myelin basic protein (h-MBP) has a molecular weight of 18.5 KD and contains 170 amino acid residues. Synthetic peptides ranging in length from about 8 to 25 residues and covering the entire...
|
|
|
7368427 |
GLP-1 analogues
The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to...
|
|
|
7368428 |
Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
Methods and compositions for restoring sensitivity to the antitumorigenic effects of antiestrogen therapy and/or cytotoxic therapy and inducing cell apoptosis are provided. Contacting tumor cells...
|
|
|
7368127 |
Biomedical devices with peptide containing coatings
Biomedical devices with stable peptide coatings are provided. The coatings are formed by incorporating at least one latent reactive component into the reactive mixture, forming a medical device...
|
|
|
7364732 |
Method for treating inflammation
A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its...
|
|
|
7365051 |
Compounds with improved cartilage-inducing and/or bone-inducing activity
The present invention concerns a bioactive implant material having a cartilage-inducing and/or bone-inducing activity composed of two components A and B, of which A is a bone-inducing and/or...
|
|
|
7365052 |
Tendon-inducing methods
Compositions of proteins with tendon/ligament-like tissue inducing activity are disclosed. The compositions are useful in the treatment of tendinitis and tendon or ligament defects and in related...
|
|
|
7361637 |
Hypotensors
There are provided a method for selection of a substance which is capable of controlling activation of prorenin where an adjusting ability of the activation of prorenin by protein-protein...
|
|
|
7361350 |
Use of an IL-1 antagonist for treating arthritis
Methods of treating, inhibiting, or ameliorating arthritis, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, or juvenile rheumatoid arthritis, in a human...
|
|
|
7361642 |
Canine specific growth hormone releasing hormone
A composition and a method of increasing growth hormone (“GH”) values in a canine or dog, and more specifically, a canine- or dog-specific growth hormone releasing hormone (“dGHRH”), or...
|
|
|
7361638 |
Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect
This invention relates to a medicine for humans, and particularly to a pharmaceutical combination comprising Epidermal Growth Factor (EGF) and Growth Hormone secretagogue hexapeptide (GHRP) for use...
|
|
|
7361358 |
Treatment of a facial pain by peripheral administration of a neurotoxin
Methods for treating a non-spasm caused pain by peripheral administration to a patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin.
|
|
|
7357934 |
Intracranial botulinum toxin therapy for focal epilepsy
Methods for treating and/or curing epilepsy by intracranial administration of a botulinum toxin.
|
|
|
7358237 |
Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2
Cyclooxygenase (COX2) and inducible nitric oxide synthase (iNOS) are two major inflammatory mediators. Inducible NOS specifically binds to COX2 and S-nitrosylates it, enhancing COX2 catalytic...
|
|
|
7358231 |
Pancreatic cancer secreted targets and uses thereof
The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic...
|
|
|
7358230 |
Conserved diaphanous-related formin autoregulatory domain (DAD)
The Diaphanousrelated formins (DRFs) constitute a subclass of FH proteins known for their ability to bind activated Rho subfamily of small GTP-binding proteins which link FH proteins to cellular...
|
|
|
7358254 |
Method for treating atherosclerosis employing an aP2 inhibitor and combination
A method is provided for treating atherosclerosis and related diseases, employing an aP2 inhibitor or a combination of an aP2 inhibitor and another antiatherosclerotic agent, for example, an HMG...
|
|
|
7358076 |
Sublancin lantibiotic produced by Bacillus subtilis 168
An antimicrobial peptide produced by Bacillus subtilis 168 was isolated and characterized and named sublancin 168. The invention includes DNA encoding for the sublancin 168 peptides and peptides...
|
|
|
7358225 |
Cloning and recombinant production of CRF receptor(s)
In accordance with the present invention, there are provided novel G-protein-coupled receptor proteins (CRF-R) characterized by having sufficient binding affinity for corticotropin releasing factor...
|
|
|
7358227 |
Pharmaceutical compositions comprising bone morphogenetic protein monomers for inhibiting bone formation
The present invention relates to a pharmaceutical composition containing a mixture of stable folding variants of recombinant bone morphogenic proteins (rBMPs) and its use in therapy, especially in...
|
|
|
7354579 |
Method of treating cancer with a VEGF antagonist and an anti-proliferative agent
Methods of treating cancer and/or reducing or inhibiting tumor growth in a subject in need thereof, comprising administering pharmaceutical composition comprising a vascular endothelial cell growth...
|
|
|
7354903 |
Cosmetic compositions containing short bioactive peptides
Short bioactive peptides containing phenylalanine, leucine, alanine, and lysine residues are disclosed. The peptides can be used in antibacterial, antifungal, anticancer, and other biological...
|
|
|
7354581 |
Therapeutic combination of a VEGF antagonist and anti-hypertensive agent
Disclosed are compositions and methods for treating a disease or condition related to angiogenesis with a vascular endothelial growth factor (VEGF) inhibitor and one or more anti-hypertensive...
|
|
|
7354901 |
Production of recombinant BMP-2
In order to recombinantly prepare a biologically active protein of the TGF-β superfamily, a protein, whose amino terminus consists of the pro sequence of a protein of the TGF-β superfamily, or...
|